



Technical Report No. 88

Microbial Data Deviation Investigations in the Pharmaceutical Industry

Microbial Data Deviation Investigations in the Pharmaceutical Industry Team

Authors & Contributors

Julie Barlasov-Brown, Merck & Co, Inc. (Co-chair)

Marc Glogovsky, ValSource, Inc. (Co-Chair)

Christopher Murdock, Ph.D., Bristol-Myers Squibb (Co-chair)

Ed Balkovic, Ph.D., Sanofi/Genzyme (retired)

Kim Sobien, PETNET Solutions, a Siemens Company

Thomas Arista, U.S. Food and Drug Administration

Tony Cundell, Ph.D., Microbiological Consulting, LLC

Osama Elrashidy, Bayer Healthcare (retired)

Dennis E. Guilfoyle, Ph.D., Johnson & Johnson

Jeanne Moldenhauer, Excellent Pharma Consulting

Jim Polarine, STERIS

Paula Peacos, ValSource, Inc.

Miriam Rozo, Johnson & Johnson

Marsha Steed, National Resilience, Inc.

Jonathan Stewart, Cook Animal Health

Radhakrishna Tirumalai, U.S. Pharmacopeial Convention

Vanessa Vasadi-Figueroa, Quality Executive Partners, Inc.

Microbial Data Deviation Investigations in the Pharmaceutical Industry

Technical Report No. 88

ISBN: 978-1-945584-30-5

© 2022 Parenteral Drug Association, Inc.

All rights reserved.



Table of Contents

1.0 INTRODUCTION	1	4.2.5 Biological Indicators Investigations	21
1.1 Purpose.....	1	4.2.6 Aseptic Process Simulation Failures (Media Fills)	21
1.2 Scope	1	4.2.7 Environmental Monitoring.....	22
2.0 GLOSSARY OF TERMS.....	2	4.2.8 Utilities Monitoring.....	23
2.1 Abbreviations/Acronyms	4	4.3 Phase I: Conclusion and Next Steps	24
3.0 MICROBIOLOGIST ROLES AND RESPONSIBILITIES.....	5	5.0 PHASE II: MANUFACTURING INVESTIGATION ...	25
3.1 Laboratory Microbiologist Responsibilities.....	5	5.1 Root Cause Analysis.....	26
3.2 Microbiologist Role in a Manufacturing Investigation	5	5.2 Phase II: Specific Points to Consider.....	31
3.3 Microbiology Laboratory Management Responsibilities	6	5.2.1 Sterility-Positive Investigations	31
3.4 Subject Matter Expert Responsibilities.....	6	5.2.2 Determining Sources of Bacterial Endotoxin	33
3.5 Quality Control Unit Responsibilities	6	5.2.3 Pharmaceutical Ingredient-Related Investigations	34
4.0 PHASE I: CONDUCTING THE MICROBIOLOGY LABORATORY INVESTIGATION.....	7	5.2.4 Evaluation of Confirmed Mycoplasma Contamination.....	35
4.1 Microbial Identification	11	5.2.5 Component (Container Closure) Investigations	36
4.2 Phase I: Specific Points to Consider.....	12	5.2.6 Environmental Monitoring.....	37
4.2.1 Sterility Testing Investigations	12	5.2.7 Investigation of Confirmed Contamination During A Process Simulation/Media Fill	39
4.2.2 Bacterial Endotoxins Testing Investigations..	16	5.2.8 Utilities Monitoring.....	40
4.2.3 Antimicrobial Effectiveness Testing Investigations	19	6.0 CONCLUSIONS.....	43
4.2.4 Mycoplasma Testing Investigations.....	19	7.0 REFERENCES.....	44

FIGURES AND TABLES INDEX

Figure 4.0-1	Fishbone Diagram Showing Inputs of Microbial Testing during Root Cause Analysis	Table 5.1-1	Factors to Consider in Root Cause Analysis
	7		27
Table 4.0-1	Sample Questions for Laboratory Investigations.....	Figure 5.1-1	Fishbone Diagram Examining Microbial Contamination of a Drug Product
	8		27
Table 4.1-1	General Points to Consider in Microbial Identification	Table 5.1-2	Root Cause Evaluation and Follow-Up
	12		31
Table 4.2.1-1	Data of the Sterility Testing Facility Show a Fault.....	Table 5.1-3	CAPA Determination.....
	14		31
Table 4.2.1-2	Testing Procedure Used Reveals a Fault ...	Table 5.2.1-1	Questions for Investigating Manufacturing/Process Sources Associated with a Confirmed Sterility Batch Failure
	15		32
Table 4.2.3.1-1	Questions Concerning Antimicrobial Effectiveness Testing.....	Table 5.2.2-1	Endotoxin-Related Investigation Considerations
	19		34
Table 4.3.4.1-1	Culture-Based Mycoplasma Testing Considerations.....	Table 5.2.3-1	Additional considerations for raw material investigations.....
	20		35
Table 4.3.4.1-2	Mycoplasma PCR-Based Detection Testing Considerations.....	Table 5.2.6-1	Potential Sources of Contamination...
	21		37
Table 4.3.7-1	Environmental Monitoring: Questions Concerning Laboratory and Sampling.....	Table 5.2.6.2-1	Examples of Corrective Actions
	22		39
		Table 5.2.7-1	Possible Origin of Representative Microorganisms.....
			40



Bethesda Towers
4350 East West Highway
Suite 600
Bethesda, MD 20814 USA
Tel: +1 (301) 656-5900
Fax: +1 (301) 986-0296
E-mail: info@pda.org
Web site: www.pda.org